A	B	C	D	E	F	G	H	I	J	K	L
1
2		Name	Indication	Rights	Approved	Class	Admin	IP		Price USD	66.98
3		Soliris (eculizumab)	PNH	1	3/16/2007	C5 mab	IV			Shares	1560	Q222
4		Tagrisso (osimertinib)	NSCLC	1	11/13/2015	EGFR TKI	Oral	2032		MC USD	104488.8
5		Imfinzi (durvalumab), FKA MEDI-4736	NSCLC	1	5/1/2017	PD-L1 mab	IV			Cash USD	0	Q222
6		Symbicort (budenoside/formoterol)	Asthma	1			Inhaled			Debt USD	24689	Q222
7		Onglyza (saxagliptin)	Type 2 Diabetes	BMY		DPP4	Oral			EV USD	129177.8
8		Brilinta (ticagrelor)	ACS	1		Platelet Inhibitor	Oral
9		Lynparza (olaparib)	Cancer	MRK	12/19/2014	PARP inhibitor	Oral	2024
10		Ultomiris (ravulizumab)	PNH	1	12/21/2018
11		Calquence
12		Nexium
13		Fasenra
14		Crestor
15		Koselugo (selumetinib)	Neurofibromas	MRK, ARRY/PFE		MEK1/MEK2	Oral
16		Farxiga (dapaglifozin)	Type 2 Diabetes	BMY	1/8/2014	SGLT2 Inhibitor	Oral	2025
17		Iressa (gefitinib)	NSCLC	1		Anti-EGFr	Oral
18					Phase			Class
19		MEDI-546	Scleroderma	1	I	Anti-interferon
20		MEDI-545	SLE	1	II	Anti-interferon
21		8309	COPD	1	I/II	chemokine antagonist
22		MEDI-575	Cancer	1	I	PDGF
23		MEDI-547	Cancer	SGEN	I	Epha2
24
25		7/29/22: 1H22 results					January 2008: Filed motavizumab.
26							March 2008: Crestor JUPITER study stopped early for efficacy.
27							July 31 2009: Onglyza approved.
28							Q409: Court case for Seroquel?
29							January 2010: Court case for Nexium.
30							February 2010: Court case for Crestor.
31							Q2/Q3 2010: Recentin GBM data.
32							YE 2010: Seroquel XR EMEA decision
33
34
35
36
37
38
39							9/27/22: Koselugo approved in Japan